<DOC>
	<DOCNO>NCT00874211</DOCNO>
	<brief_summary>RATIONALE : Gathering information often osteonecrosis jaw occurs patient receive zoledronic acid bone metastasis may help doctor learn disease provide best follow-up care . PURPOSE : This clinical trial study osteonecrosis jaw patient cancer receive zoledronic acid bone metastasis .</brief_summary>
	<brief_title>S0702 : Osteonecrosis Jaw Patients With Cancer Receiving Zoledronic Acid Bone Metastases</brief_title>
	<detailed_description>OBJECTIVES : Primary - To prospectively access cumulative incidence osteonecrosis jaw ( ONJ ) 3 year cancer patient bone metastasis receive zoledronic acid treatment . Secondary - To describe clinical presentation natural history ONJ . - To identify potential risk factor development ONJ . - To estimate cumulative incidence ONJ 3 year different tumor type ( i.e. , breast cancer , multiple myeloma , prostate cancer , lung cancer , cancer ) . - To good define patient-related outcome ONJ . OUTLINE : This multicenter study . Patients undergo dental assessment baseline every 3-6 month 3 year .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Plasmacytoma</mesh_term>
	<mesh_term>Osteonecrosis</mesh_term>
	<mesh_term>Zoledronic acid</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Participant must bone metastasis multiple myeloma , solid tumor , malignancy intravenous bisphosphonate clinical indication treatment metastatic bone disease Treatment osteoclast inhibition clinically indicate Must plan receive zoledronic acid* within next 30 day NOTE : *Osteoclast inhibition therapy continue thereafter clinically indicate . No prior diagnosis osteonecrosis jaw Patients previously treat osteoclast inhibition therapy eligible , provide follow criterion apply : Prior osteoclast inhibition low bone mass ( osteoporosis osteopenia ) : Patients may previously receive 3 dos osteoclastinhibiting therapy denosumab , IV ibandronate , pamidronate , zoledronic acid low bone mass ( osteopenia osteoporosis ) within 3 year prior registration Prior oral bisphosphonate therapy osteoporosis osteopenia dose time prior registration allow Prior exposure medication use treat low bone mass osteoporosis osteopenia dosing permit Prior osteoclast inhibition metastatic bone disease ( tumor involve bone ) : Patients may previously receive osteoclastinhibiting therapy denosumab , ibandronate ( oral IV cancer dose ) , pamidronate , zoledronic acid treat metastatic bone disease within 180 day prior registration Patients receive regimen metastatic bone disease prior 180 day registration eligible Prior osteoclastinhibiting therapy high dose outlined time prior registration allow PATIENT CHARACTERISTICS : Zubrod performance status 03 Patients may acutely ill spinal cord compromise , hypercalcemia malignancy , process may study candidate acute condition address performance status improve 03 Not pregnant nursing Negative pregnancy test Willing physically able comply study procedures assessment Willing provide information personal history , include tobacco alcohol use , pain assessment Willing provide access prior future dental information No prior malignancy except follow : Adequately treat basal cell carcinoma squamous cell carcinoma skin In situ cervical cancer Adequately treat stage I II cancer patient currently complete remission Any cancer patient diseasefree 5 year PRIOR CONCURRENT THERAPY : See Disease Characteristics No history radiation maxillofacial area administer therapeutic intent treatment cancer Concurrent participation therapeutic nontherapeutic clinical trial allow The sum prior IV bisphosphonate dos must great 10 The sum prior denosumab dos must great 8 The total IV bisphosphonate denosumab use indication must great 12 dos</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>120 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>bone metastasis</keyword>
	<keyword>unspecified adult solid tumor , protocol specific</keyword>
	<keyword>refractory multiple myeloma</keyword>
	<keyword>stage I multiple myeloma</keyword>
	<keyword>stage II multiple myeloma</keyword>
	<keyword>stage III multiple myeloma</keyword>
	<keyword>male breast cancer</keyword>
	<keyword>recurrent breast cancer</keyword>
	<keyword>stage IA breast cancer</keyword>
	<keyword>stage IB breast cancer</keyword>
	<keyword>stage II breast cancer</keyword>
	<keyword>stage IIIA breast cancer</keyword>
	<keyword>stage IIIB breast cancer</keyword>
	<keyword>stage IIIC breast cancer</keyword>
	<keyword>stage IV breast cancer</keyword>
	<keyword>recurrent prostate cancer</keyword>
	<keyword>stage I prostate cancer</keyword>
	<keyword>stage IIB prostate cancer</keyword>
	<keyword>stage IIA prostate cancer</keyword>
	<keyword>stage III prostate cancer</keyword>
	<keyword>stage IV prostate cancer</keyword>
	<keyword>recurrent non-small cell lung cancer</keyword>
	<keyword>stage I non-small cell lung cancer</keyword>
	<keyword>stage II non-small cell lung cancer</keyword>
	<keyword>stage IIIA non-small cell lung cancer</keyword>
	<keyword>stage IIIB non-small cell lung cancer</keyword>
	<keyword>stage IV non-small cell lung cancer</keyword>
	<keyword>extensive stage small cell lung cancer</keyword>
	<keyword>limited stage small cell lung cancer</keyword>
	<keyword>recurrent small cell lung cancer</keyword>
</DOC>